Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mjafi.2020.08.004 http://scihub22266oqcxt.onion/10.1016/j.mjafi.2020.08.004 32895599!7467067!32895599     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+J+Armed+Forces+India 2020 ; 76 (4): 370-376 Nephropedia Template TP {{tp|p=32895599|t=2020. Favipiravir: A new and emerging antiviral option in COVID-19 |pdf=|usr=}}{{32895599}} gab.com Text Favipiravir: A new and emerging antiviral option in COVID-19 JO: Med J Armed Forces India http://www.kidney.de/pget.php?&tw=1&pmid=32895599 #FOAvip With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. Twit Text FOAVip Favipiravir: A new and emerging antiviral option in COVID-19 ????Med J Armed Forces India http://www.kidney.de/pget.php?&tw=1&pmid=32895599 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32895599 #FOAvip English Wikipedia <ref>{{Cite pmid|32895599}}</ref> Favipiravir: A new and emerging antiviral option in COVID-19 #MMPMID32895599 Agrawal U; Raju R; Udwadia ZF Med J Armed Forces India 2020[Oct]; 76 (4): 370-376 PMID32895599show ga With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world. With the paucity of new drugs to combat this disease, the medical community is in a race to identify repurposed drugs that may be effective against this novel coronavirus. One of the drugs which has recently garnered much attention, especially in India, is an anti-viral drug originally designed for influenza, called favipiravir. In this article, we have tried to provide a comprehensive, evidence-based review of this drug in the context of the present pandemic to elucidate its role in the management of COVID-19. äFavipiravir: A new and emerging antiviral option in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing